BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx (NASDAQ: BLRX) initiated a first-in-human Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas on March 26, 2026. GLIX1 is an oral TET2 activator with preclinical anti-tumor activity, blood-brain-barrier penetration and favorable toxicology.The Phase 1 cohort will recruit up to 30 patients to establish MTD/recommended dose; initial Phase 1 data are anticipated in H1 2027. Three academic centers (NYU Langone, Northwestern, Moffitt) will participate.

#BLRX BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

www.stocktitan.net/news/BLRX/bio-line-rx-an...

BioLineRx says its brain cancer drug enters human testing this month Cash totaled $20.9M at year-end, funding operations into H1 2027. BioLineRx also extended GLIX1 patent coverage to 2040 and expects mPDAC data in 2026.

#BLRX BioLineRx Reports 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLRX/bio-line-rx-re...

ICAO: 789204
Owner: CATHAYPACIFIC
Flt: CPA812 BLRX A359 HKG-BOS
Time: 2026-02-15 21:21:22 EST
Min Alt: 9000 ft
Min Dist: 0.99 nm (24deg NNE)
Squawk: 2220
dev adsb planefence by kx1t - sdr-e airplanes flightaware

#BLRX: Stem Cell Mobilization Presentation at ASH buff.ly/l1XSHhT

#BLRX BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLRX/bio-line-rx-re...

This Week #EARNINGS

#CAAP #BLRX #LOT #A #ZM #KEYS
#NIO #BABA #NIO #KSS #BABA #WOOF #URBN #WDAY #ZS #ADSK
#DE #LI #EH #ALAR #AMBR #CHA #BTC

Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors Hemispherian AS, a biotechnology company pioneering first-in-class TET2-activating therapeutics for difficult-to-treat cancers, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the patent application titled“ Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies”. The patent covers the use of...

#BLRX Hemispherian Announces USPTO Notice of Allowance for Key GLIX1 Patent Covering Majority of Solid Tumors

www.stocktitan.net/news/BLRX/hemispherian-a...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx (NASDAQ: BLRX) announced a U.S. Patent and Trademark Office Notice of Allowance for a patent titled Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies (Appl. Ser. No. 18/602,969) covering use of GLIX1 in cancers where cytidine deaminase (CDA) is not over-expressed.The patent broadens GLIX1's intellectual property, extending protection for the treatment of cancer until 2040 with a possible patent-term extension up to five years. The company estimates >90% of cancers fall within the patent's CDA expression threshold. Corresponding international applications are pending, and GLIX1 combination claims with PARP inhibitors are at the international patent stage with potential protection to 2044 if granted. BioLineRx plans a first-in-human glioblastoma study in Q1 2026.

#BLRX BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

www.stocktitan.net/news/BLRX/bio-line-rx-an...

#BLRX: A Venture into GBM buff.ly/dgAvMME

#BLRX: ASCO Poster & Abstract buff.ly/IIA6ZdS

BioLineRx Plans New Drug Pipeline Deal as Cash Runway Stretches to 2027 Biotech firm reports $28.2M cash position and extends runway into H1 2027. Evaluating oncology and rare disease assets for potential 2025 pipeline expansion. Get insights.

#BLRX BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLRX/bio-line-rx-re...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RRGB, #NVS, #BLRX, #LAES, #YMM

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#HIMS, #RBLX, #RRGB, #NVS, #BLRX

#OptionFlow #OptionsTrading #Trading

BREAKING NEWS: ( NASDAQ: #BLRX ) PRISM Mid-Day Movers: Biopharma Results and Enhanced Coverage for AI Cybersecurity Drive Index Movement

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RRGB 4.2x
2. #NVS 2.6x
3. #BLRX 2.5x
4. #LAES 2.0x
5. #YMM 2.0x

#OptionFlow #OptionsTrading #Trading

Nasdaq Down 100 Points; Chicago PMI Dips In May - Nuburu (AMEX:BURU), BioLine Rx (NASDAQ:BLRX)

Nasdaq Down 100 Points; Chicago PMI Dips In May read more

www.benzinga.com/cannabis/25/05/45698911/...

#BLRX #BURU #BWNB #CLGN #Earnings #Equities #GITS #MDCX #Mid #Morning #Market

Result Details

#BLRX: First Quarter Results buff.ly/ANGem7L

#BioLineRx ( #BLRX) shines in Q1 2025! Advancing APHEXDA® for stem cell mobilization and expanding oncology pipeline with promising trials. Strong financials with $40.2M in cash fuel growth. Exciting times for biotech innovation!

prismmarketview.com/biolinerx-hi...

BioLineRx Reports Earnings Success: New Cancer Drug Data Shows Complete Response in Pancreatic Trial Latest earnings reveal $26.4M cash position and promising pancreatic cancer trial results. New PDAC treatment data to be unveiled at ASCO 2025. Get full insights.

#BLRX BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLRX/bio-line-rx-re...

#BLRX: 2024 Financial Results buff.ly/h59wu7y

HeatMaps - ORTEX

📢 Earnings Are In!

This morning’s earnings lineup includes #BCLI, #BLRX, #FTCI, #NNOX, #WKHS, and others.

Track the impact on the market with our Earnings Heat Map:
app.ortex.com/earnings/hea...

#Earnings #Markets #Investing

BioLineRx Transforms with 502% Revenue Surge and $97M Potential Deal Record-breaking revenue growth and $10M upfront licensing deal strengthen BioLineRx's position. Extended cash runway through 2026 supports strategic pivot. Full analysis inside.

#BLRX BioLineRx Reports 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BLRX/bio-line-rx-re...

#BLRX: Aphexda Transition Progressing buff.ly/4hHQ4qv

JUST IN: ( NASDAQ: #BLRX ) BLRX announced stock split 1-40

BioLineRx Secures $25M Upfront in Major Licensing Deals, Extends Cash Runway to 2026 BioLineRx transforms with Ayrmid and GloriaBio partnerships, securing $25M upfront payments plus $337M potential milestones. Company restructures with lean focus and solid tumor rights.

#BLRX BioLineRx Issues Letter to Shareholders

www.stocktitan.net/news/BLRX/bio-line-rx-is...

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 BioLineRx adjusts ADS ratio from 15:1 to 600:1, effectively implementing 1-for-40 reverse split. $29.5M cash position supports development through H2 2026 with $12M annual burn rate.

#BLRX BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

www.stocktitan.net/news/BLRX/bio-line-rx-an...

BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants BioLineRx secures $10M through 50M ADS offering with additional warrants, priced at $0.20. Funds targeted for R&D advancement and pipeline expansion, closing January 2024.

#BLRX BioLineRx Announces $10 Million Registered Direct Offering

www.stocktitan.net/news/BLRX/bio-line-rx-an...

#BLRX BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

www.stocktitan.net/news/BLRX/bio-line-rx-re...